Market Overview:
The global ADHD medications market is expected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of ADHD, rising awareness about ADHD and its treatment options, and the launch of novel drugs for the treatment of ADHD. The global ADHD medications market is segmented on the basis of type into stimulant and non-stimulant drugs. The stimulant drugs segment is expected to account for a larger share in terms of revenue in 2018, owing to their high efficacy in treating symptoms associated with ADHD. However, over time, the non-stimulant drug segment is projected to witness higher growth due its lesser side effects as compared with stimulants. On the basis of application, adults are estimated to account for a larger share in terms revenue generated by this market during 2018–2030; however children are anticipated exhibit faster growth rates through 2030 owing growing awareness about diagnosis.
Product Definition:
ADHD medications are drugs that are prescribed to people who have been diagnosed with ADHD. These medications help to improve attention, focus, and reduce hyperactivity and impulsiveness in people who take them. They are important because they can help people with ADHD to function better in daily life.
Stimulant:
Stimulant is a drug that increases the body's alertness and awareness. Stimulants are drugs that cause stimulation or excitation of the brain. They have three general categories, Central Nervous System (CNS) stimulants, Locomotor Stimulators, and Respiratory stimulants. CNS stimulants are generally prescribed for patients suffering from narcolepsy as well as attention deficit hyperactivity disorder (ADHD).
Non-stimulant:
Non-stimulant drugs are those that produce minimal activation in the wakefulness centers of the brain. They do not send signals to the body to wake up or feel sleepiness. The most commonly used non-stimulants for ADHD are Atomoxetine and Guanfacine. These medications can be used as monotherapy or in combination with other stimulants such as Amphetamine, Methylphenidate, and Lisdexamfetamine.
Application Insights:
ADHD medications are used in the treatment of ADHD for children and adults. The adult application segment held the largest share of over 60% in 2017. This is due to a large patient base that has remained untreated despite medical treatments such as therapy and antidepressants being ineffective. Furthermore, increasing awareness about diagnosis and treatment among adults is expected to boost market growth during the forecast period.
The U.S., Germany, UK, Japan, China and India are projected to account for high demand owing to high prevalence of ADHD coupled with advanced healthcare facilities & infrastructure which will result in higher usage rates of stimulant medication during the forecast period. On the other hand countries such as Brazil have one of the highest number of patients diagnosed but do not have a well-developed healthcare system which may hinder market growth there during this study¢â‚¬â„¢s timeframe; however it will stimulate demand once fully developed resulting in an estimated CAGR around 7%.
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. The region is expected to maintain its position during the forecast period due to increasing awareness about mental health, availability of effective treatment, and presence of a large target population. Moreover, rising prevalence of obesity coupled with high disposable income is anticipated to fuel growth over the forecast period.
Asia Pacific is estimated to be fastest-growing region from 2018 to 2030 owing to improving economic conditions and growing healthcare expenditure in emerging countries such as China and India. Growing awareness among people regarding mental disorders & their treatments will also support regional market growth over the coming years.
Growth Factors:
- Increasing prevalence of ADHD: The increasing prevalence of ADHD is one of the key growth drivers for the global ADHD medications market. According to a study by the Centers for Disease Control and Prevention (CDC), around 11% of children aged 4-17 years in the U.S. have been diagnosed with ADHD as of 2011. This number is expected to increase in future, owing to factors such as rising awareness about ADHD and its diagnosis, and increasing incidence of childhood obesity (a risk factor for developing ADHD).
- Growing demand from adults: The demand for ADHD medications from adults is another major growth driver for this market. According to a study by Medco Health Solutions, Inc., around 2 million American adults were treated for ADHD in 2010, and this number is expected to grow significantly in future due to growing awareness about adult-onset ADD/ADHD and increased access to treatment options.
- Rising R&D investments: Pharmaceutical companies are investing heavily in R&D activities aimed at developing new drugs specifically targeted at treating symptoms associated with ADHD disorder such as impulsiveness, hyperactivity, etc., thereby fueling the growth prospects of this market segment over the forecast period 2016-2024 . For instance, Shire plc has announced plans invest USD 1 billion over next five years into research & development activities focused on neuroscience disorders including Attention Deficit Hyperactivity Disorder (ADHD). This will help expand their product offerings specifically catering to patients suffering from various forms or severity
Scope Of The Report
Report Attributes
Report Details
Report Title
ADHD Medications Market Research Report
By Type
Stimulant, Non-stimulant, ADHD Medication
By Application
Adult, Children
By Companies
Amneal Pharmaceuticals, Eli Lilly and Co., Johnson and Johnson Services, NEOS Therapeutic, Takeda Pharmaceutical, Pfizer, Lupin, Shire, Mallinckrodt, ADHD Medication
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global ADHD Medications Market Report Segments:
The global ADHD Medications market is segmented on the basis of:
Types
Stimulant, Non-stimulant, ADHD Medication
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adult, Children
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amneal Pharmaceuticals
- Eli Lilly and Co.
- Johnson and Johnson Services
- NEOS Therapeutic
- Takeda Pharmaceutical
- Pfizer
- Lupin
- Shire
- Mallinckrodt
- ADHD Medication
Highlights of The ADHD Medications Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Stimulant
- Non-stimulant
- ADHD Medication
- By Application:
- Adult
- Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the ADHD Medications Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
ADHD medications are drugs prescribed to treat ADHD. These medications help to improve the symptoms of ADHD, such as inattention, hyperactivity, and impulsiveness.
Some of the major companies in the adhd medications market are Amneal Pharmaceuticals, Eli Lilly and Co., Johnson and Johnson Services, NEOS Therapeutic, Takeda Pharmaceutical, Pfizer, Lupin, Shire, Mallinckrodt, ADHD Medication.
The adhd medications market is expected to register a CAGR of 7.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. ADHD Medications Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. ADHD Medications Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. ADHD Medications Market - Supply Chain
4.5. Global ADHD Medications Market Forecast
4.5.1. ADHD Medications Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. ADHD Medications Market Size (000 Units) and Y-o-Y Growth
4.5.3. ADHD Medications Market Absolute $ Opportunity
5. Global ADHD Medications Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. ADHD Medications Market Size and Volume Forecast by Type
5.3.1. Stimulant
5.3.2. Non-stimulant
5.3.3. ADHD Medication
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global ADHD Medications Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. ADHD Medications Market Size and Volume Forecast by Application
6.3.1. Adult
6.3.2. Children
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global ADHD Medications Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. ADHD Medications Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global ADHD Medications Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. ADHD Medications Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global ADHD Medications Demand Share Forecast, 2019-2026
9. North America ADHD Medications Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America ADHD Medications Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America ADHD Medications Market Size and Volume Forecast by Application
9.4.1. Adult
9.4.2. Children
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America ADHD Medications Market Size and Volume Forecast by Type
9.7.1. Stimulant
9.7.2. Non-stimulant
9.7.3. ADHD Medication
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America ADHD Medications Demand Share Forecast, 2019-2026
10. Latin America ADHD Medications Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America ADHD Medications Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America ADHD Medications Market Size and Volume Forecast by Application
10.4.1. Adult
10.4.2. Children
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America ADHD Medications Market Size and Volume Forecast by Type
10.7.1. Stimulant
10.7.2. Non-stimulant
10.7.3. ADHD Medication
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America ADHD Medications Demand Share Forecast, 2019-2026
11. Europe ADHD Medications Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe ADHD Medications Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe ADHD Medications Market Size and Volume Forecast by Application
11.4.1. Adult
11.4.2. Children
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe ADHD Medications Market Size and Volume Forecast by Type
11.7.1. Stimulant
11.7.2. Non-stimulant
11.7.3. ADHD Medication
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.101. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe ADHD Medications Demand Share, 2019-2026
12. Asia Pacific ADHD Medications Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific ADHD Medications Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific ADHD Medications Market Size and Volume Forecast by Application
12.4.1. Adult
12.4.2. Children
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific ADHD Medications Market Size and Volume Forecast by Type
12.7.1. Stimulant
12.7.2. Non-stimulant
12.7.3. ADHD Medication
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific ADHD Medications Demand Share, 2019-2026
13. Middle East & Africa ADHD Medications Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa ADHD Medications Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa ADHD Medications Market Size and Volume Forecast by Application
13.4.1. Adult
13.4.2. Children
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa ADHD Medications Market Size and Volume Forecast by Type
13.7.1. Stimulant
13.7.2. Non-stimulant
13.7.3. ADHD Medication
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa ADHD Medications Demand Share, 2019-2026
14. Competition Landscape
14.1. Global ADHD Medications Market: Market Share Analysis
14.2. ADHD Medications Distributors and Customers
14.3. ADHD Medications Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amneal Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly and Co.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Johnson and Johnson Services
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. NEOS Therapeutic
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Takeda Pharmaceutical
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Lupin
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Shire
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Mallinckrodt
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. ADHD Medication
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
